LIVE Q&A
We're looking at a Macro Quad transition from growth + inflation (Quad 2) to growth + inflation slowing (Quad 1), and we're using some new tools to look at which stocks perform best w/ that backdrop. Macro Quad 2 and MicroQuad 3 have been cruel to our Health Care Long ideas, but our Short Ideas have outperformed by a country mile. Join us to ask questions and see where we are with our stocks, longs and shorts, and what's changed at the margin.
Submit your questions ahead of time via , and see below for what we've got queued up to start.
|
Hedgeye House Call | Macro Shift, AMN, ATIP, TDOC, ONEM Please join us on Monday, December 6, at 2:00 PM ET Health Care Subscribers: CLICK HERE for event details (including video, materials links, and Q&A box). |
THEME & TICKER UPDATES For Monday
Macro Regime Shift | In Quad 1 where “everything goes up,” we’re looking forward to seeing some of our theses play out in the price of the stocks, not just in the fundamentals. There are names we’ve culled from the Best Ideas on our Position Monitor (i.e., we've moved EYE, NEO, and others to the Long Bench), but the ones that we’ve continued to stick with, despite frustrating performance in some cases, look even better fundamentally than when we added them.
Macro Quad Playbook | Plugging into Macro Quad 1 and the MicroQuads. Filtering for Macro Quad 1, Sector Trends, and Subgroup Headwinds and Tailwinds, we'll review a shortlist of new ideas.
Omicron | What’s the threat level (to our stocks and the public/health system)? Key differences from prior waves and what we’re watching.
U.S. Medical Economy | Health Care Employment Update for November 2021.
AMN | Tracker update, labor demand hasn’t peaked yet.
ATIP | Hiring Tracker update + recovery update.
TDOC | It's not time to cover (!) - the multiple regime transition from EV/Sales to EV/EBITDA continues to run its course.
ONEM | We have stuck with One Medical (now including Iora) all year and the market has penalized us for doing so. Meanwhile, management continues to execute. We will provide an update on our thinking and outlook.
As always, all data available upon request, and reach out to with any inquiries.
Thomas Tobin
Managing Director
Twitter
LinkedIn